
Commentary|Videos|December 15, 2023
Dr. Kukreja on key kidney cancer research presented at SUO 2023
Author(s)Urology Times staff
Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.
Advertisement
Video Player is loading.
In this video, Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s
- Poster 6: SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597] – Hyung Kim, MD
- Poster 7: Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab) – Joseph Zabell, MD
- Poster 101: Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma – Levi Holland, MD
- Poster 13: Limited utility of quantitative thresholds on 99MTC-sestamibi SPECT/CT for distinguishing renal cell carcinoma from oncocytic renal masses – Robert S. Wang, MD
- Poster 103: Comprehensive Immunogenomic Evaluation of Patients Undergoing Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade – Stephen Reese, MD
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC
2
Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC
3
Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS
4
News Network: Prostate Cancer and Bladder Cancer at ESMO 2025
5